Evidence map›Paper›PMID 40101289›Full record

ArticleHuman vaccines & immunotherapeutics2025

Human papillomavirus (HPV) vaccine clinical trials: A cross-sectional analysis of clinical trials registries.

Edison Johannes Mavundza, Tshiamo Moshading Mmotsa, Duduzile Ndwandwe

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Edison Johannes MavundzaCochrane South Africa, South African Medical Research Council, Cape Town, South Africa.ORCID 0000-0002-0890-0164
Tshiamo Moshading MmotsaCochrane South Africa, South African Medical Research Council, Cape Town, South Africa.
Duduzile NdwandweCochrane South Africa, South African Medical Research Council, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trials remain the gold standard for evaluating the effectiveness and safety of health interventions. Every clinical trial is mandated to be registered prospectively in a publicly accessible trial registry before the enrollment of the first participant. The aim of the current study was to provide a cross-sectional analysis of registered HPV vaccine clinical trials listed in the International Clinical Trials Registry Platform (ICTRP). On 05 March 2023, we searched the ICTRP for registered HPV vaccine clinical trials using the term "human papillomavirus vaccine." Two authors independently extracted data including the name of the clinical trial registry, location, recruitment status, gender of participants, phase, primary outcome, and type of sponsor. Our search of the ICTRP resulted in 437 HPV vaccine clinical trials registered between 1999 and 2022. Most of the trials were: registered retrospectively (61.3%,

Indexed as

Clinical Trials as TopicPapillomavirus InfectionsPapillomavirus VaccinesRegistriesCross-Sectional StudiesFemaleHuman Papillomavirus VirusesHumansMalePapillomavirus Vaccinesclinical trial registriesclinical trialsHuman papillomavirusInternational Clinical Trials Registry Platformvaccines

Identifiers

PMID40101289
PMCPMC12934134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.